US2266835A - Oxygen-evolving substance - Google Patents

Oxygen-evolving substance Download PDF

Info

Publication number
US2266835A
US2266835A US2266835DA US2266835A US 2266835 A US2266835 A US 2266835A US 2266835D A US2266835D A US 2266835DA US 2266835 A US2266835 A US 2266835A
Authority
US
United States
Prior art keywords
oxygen
zinc peroxide
catalyst
evolution
peroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Publication date
Application granted granted Critical
Publication of US2266835A publication Critical patent/US2266835A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06CDIGITAL COMPUTERS IN WHICH ALL THE COMPUTATION IS EFFECTED MECHANICALLY
    • G06C15/00Computing mechanisms; Actuating devices therefor
    • G06C15/04Adding or subtracting devices
    • G06C15/06Adding or subtracting devices having balance totalising; Obtaining sub-total

Definitions

  • This invention relates to oxygen-evolving preparations and to methods of increasing and controlling the oxygen evolution therefrom.
  • Certain oxygen-liberating compounds find application in therapy, because the oxygen as evolved is an efiicient antiseptic. Among such compounds, zinc peroxide is especially important. This substance is used widely in the treatment of external skin afilictions, such as ulcers, serous wounds, anaerobic streptococcus wound infections, etc.
  • the zinc peroxide should preferably remain fluify on the affected area, and should be made to decompose at such a rate that approximately twenty-five percent of its available oxygen is released over a twenty-four hour period. The more nearly uniform the release of the oxygen, the more effective the treatment.
  • 5 grammes of zinc peroxide should release at least 12 cc. of oxygen during a twentyfour hour period, and during each hour the release of oxygen should be at least as great as 0.33 cc. These are minimum requirements, and it is a desideratum to have available a zinc peroxide preparation capable of even greater and more uniform evolution of oxygen.
  • the oxygen evolved in a 24-hour period comprises only three percent or less of the theoretically available quantity.
  • the best grades of commercial zinc peroxide contain approximately 45% ZnOz.
  • Even the best of the available preparations releases considerably less than 10% of the theoretical quantity over a twenty-four hour period.
  • My invention resides in the discovery that ions of heavy metals having more than one well-defined valency series of compounds and a melting point within the range of 10601480 C. are catalysts for accelerating and controlling the release of oxygen from zinc peroxide in aqueous slurry, and that by appropriate adjustment of the relationship of the ions with respect to the zinc peroxide, as to relative concentrations, etc., as will hereinafter appear, the rate and amount of oxygen evolution may be effectively controlled for the purposes indicated.
  • Effective catalysts within the purview of my invention include manganous, cobaltous, cupric, and auric ions, derived from water-soluble and ionizable compounds of the respective metals.
  • water-soluble salts of the metals may be employed, as, for instance, manganous sulfate,
  • any compound of the metal which yields the aforementioned ions in contact with water is serviceable.
  • the preparations of my invention may be prepared by intimate admixture of the catalyst with the zinc peroxide. They are suitable for application as dressings upon admixture with a sufficient amount of water to form a slurry.
  • Table I shows the results obtainable by adding varying quantities of manganous sulfate to the zinc peroxide.
  • the mixture is made into a slurry, by the addition of water.
  • varying quantities of a tenth-molar solution of the catalyst were admixed with a slurry of 2 grams of zinc peroxide in about 20 cc, of water.
  • manganous sulfate illustrated in Table I
  • other compounds of other heavy metals of the type designated any compound of these metals which will furnish ions olution is suitable for use according to my intention.
  • cupric sulphate, cobaltous sulphate. auric chloride, etc. may be employed, and act as catalysts on zinc peroxide for medicinal use to increase the oxygen evolution at least twofold over the uncatalyzed substance.
  • the rate of oxygen evolution may be controlled, within by varying the concentration of the chosen catalyst.
  • manganous sulphate is approximately ten times as efficient in increasing the rate of, oxygen evolution as cupric sulfate, cobaltous sulfate, or auric chloride.
  • the optimum range of concentration of manganous sulfate is from 0.01 to 0.50 cc. of tenth-molarMnSOi solution per gram of zinc peroxide.
  • the quantity of M11304 should be approximately within the range from 0.015, to 0.75 gm. per grams of zinc peroxide.
  • the relatively less active catalyst can obviously be adjusted for adaptation to any given service requirements by appropriate increase in the amount of the catalyst to that of the zinc peroxide.
  • the preparations contemplated herein comprise dry zinc peroxide and dry catalyst. which may be handled separately or in admixture.
  • the dressings may be prepared extemporaneously by making a mixture of the zinc peroxide and catalyst into aslurry, or varying quantities of appropriate solutions of the catalyst may be added to make a slurry with the zinc peroxide.
  • the zinc peroxide best adapted for the medicinal use of oxygen in situ as referred to herein, is preferably prepared by reacting zinc chloride with sodium peroxide.
  • the zinc peroxide thus prepared is more definitely responsive to the action of the catalyst for the purposes of this invention over that: prepared, for instance, by the reaction of zinc oxide with hydrogen peroxide.
  • A. preparation comprising zinc peroxide and an oxygen-evolving catalyst in the form of a water-soluble ionizable compound of gold.
  • an aqueous slurry comprising zinc peroxide and a catalyst consisting of auric chloride.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Computer Hardware Design (AREA)
  • Computing Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Patented Dec. 23, 1941 OXYGEN-EVOLVING SUBSTANCE Thomas J. Webb, Princeton, N. 8., assignor to Merck & 00., Inc., Bahway, N. 3., a corporation of New Jersey No Drawing.
Original application February 17,
1938, Serial No. 191,061. Divided and this application January 28, 1941, Serial No. 376,368
2 Claims.
This application is a division of my co-pending application Serial No. 191,061, filed February 17, 1938.
This invention relates to oxygen-evolving preparations and to methods of increasing and controlling the oxygen evolution therefrom.
Certain oxygen-liberating compounds find application in therapy, because the oxygen as evolved is an efiicient antiseptic. Among such compounds, zinc peroxide is especially important. This substance is used widely in the treatment of external skin afilictions, such as ulcers, serous wounds, anaerobic streptococcus wound infections, etc.
In order to be thoroughly effective, the zinc peroxide should preferably remain fluify on the affected area, and should be made to decompose at such a rate that approximately twenty-five percent of its available oxygen is released over a twenty-four hour period. The more nearly uniform the release of the oxygen, the more effective the treatment.
According to recent findings of the medical profession, 5 grammes of zinc peroxide should release at least 12 cc. of oxygen during a twentyfour hour period, and during each hour the release of oxygen should be at least as great as 0.33 cc. These are minimum requirements, and it is a desideratum to have available a zinc peroxide preparation capable of even greater and more uniform evolution of oxygen.
7 The zinc peroxide, per se, now available on the market has many disadvantages. Many of those preparations tend to cake into a cement" on the wounds, and in some cases it is practically impossible to remove them. This is associated with meagre evolution ofoxygen, and therefore, increased and more uniform oxygen evolution is desirable in order to obviate caking, as well as for its antiseptic action.
Further, with many of the preparations nowavailable, the oxygen evolved in a 24-hour period comprises only three percent or less of the theoretically available quantity. The best grades of commercial zinc peroxide contain approximately 45% ZnOz. Under ordinary conditions, even the best of the available preparations releases considerably less than 10% of the theoretical quantity over a twenty-four hour period. With almost all of the presently available preparations, there is a tendency toward an initial burst of oxygen during the first hour, followed by a decrease so marked that during the last hours of a twenty-four hour period the minimum of 0.33 cc. per hour is barely met even under the most favorable conditions.
As it is, in order to meet the minimum requirements of the medical profession as to' the amount and rate of oxygen evolution, it is necessary to pre-heat the zinc peroxide preparations now available on the market for at least four hours at a temperature of about C. This temperature is extremely critical; temperatures below 140 C. are not effective, while temperatures above 140 C. result in decomposition and loss of oxygen. Great care is required in the pre-heating process in order to obtain a uniform material.
From the foregoing it will be seen that zinc peroxide, as now available, possesses marked disadvantages which interfere with its most effective use in therapy.
I have now made a group of zinc peroxide preparations which avoid these disadvantages, are easily prepared for application, and which satisfy the requirements for medicinal use in every respect.
By means of my invention, it is possible for the first time to utilize as much as fifty percent or more of the total available oxygen-contained in zinc peroxide. The evolution of the gas may be rendered substantially uniform, and it more than meets the minimum requirement for oxygen evolution over a prolonged period, even up to 72 hours of application under favorable, conditions.
. Furthermore, these new preparations do not require the pre-heating step referred to above.
My invention resides in the discovery that ions of heavy metals having more than one well-defined valency series of compounds and a melting point within the range of 10601480 C. are catalysts for accelerating and controlling the release of oxygen from zinc peroxide in aqueous slurry, and that by appropriate adjustment of the relationship of the ions with respect to the zinc peroxide, as to relative concentrations, etc., as will hereinafter appear, the rate and amount of oxygen evolution may be effectively controlled for the purposes indicated.
Effective catalysts within the purview of my invention include manganous, cobaltous, cupric, and auric ions, derived from water-soluble and ionizable compounds of the respective metals. Preferably, water-soluble salts of the metals may be employed, as, for instance, manganous sulfate,
cupric sulfate, auric chloride, cobaltous sulfate,
etc. However, any compound of the metal which yields the aforementioned ions in contact with water is serviceable.
The preparations of my invention may be prepared by intimate admixture of the catalyst with the zinc peroxide. They are suitable for application as dressings upon admixture with a sufficient amount of water to form a slurry.
In order to illustrate the manner in which the catalysts function to accelerate and control evolution of oxygen from the zinc peroxide, the following experimental data will be of service.
. Table I below shows the results obtainable by adding varying quantities of manganous sulfate to the zinc peroxide. In practice, the mixture is made into a slurry, by the addition of water. For the purpose of the present exemplification, varying quantities of a tenth-molar solution of the catalyst were admixed with a slurry of 2 grams of zinc peroxide in about 20 cc, of water.
From the table, it will be seen that although the amount of oxygen released by the zinc peroxide without the catalyst in $4; of an hour, for example, is not much less than that released by samples containing the catalyst over the same period, this includes an initial burst of oxygen, and represents about of the total quantity released over a 24-hour period, whereas the oxygen evolved in A; hour by the zinc peroxide containing a catalyst in accordance with my invention represents only a small proportion of the total oxygen which thereafter is released more or less uniformly and continuously over the 24-hour period.
For the manganous sulfate illustrated in Table I, there may be substituted other compounds of other heavy metals of the type designated; any compound of these metals which will furnish ions olution is suitable for use according to my intention. Thus, cupric sulphate, cobaltous sulphate. auric chloride, etc., may be employed, and act as catalysts on zinc peroxide for medicinal use to increase the oxygen evolution at least twofold over the uncatalyzed substance.
The selection of the specific catalytic compound will be governed by its suitability for medicinal purposes. Thus, for the manganese, copper, and cobalt, the method has been specifically illustrated in terms of the sulfate, whereas in the case of gold, the chloride is the most conveniently available compound. However, the action of the materials used depends upon the catalytic function of the metal ions as described, and therefore any appropriate water-soluble ionizable compound may be used, as will be obvious to those skilled in the art.
For purposes of comparison, several 2-gram samples of zinc peroxide, without catalyst, were made into a slurry with water and the oxygen evolution measured. The quantity of oxygen evolved over various periods is given in Table II below:
From a comparison of Tables 3'. and TI, it is apparent that when zinc peroxide for medicinal use is combined with a catalyst in accordance with my invention, the oxygen evolution is increased approximately l-fold over the oxygen evolved from uncatalyzed zinc peroxide such as is now available.
Further, from Table I, it will be noted that, according to my invention, the rate of oxygen evolution may be controlled, within by varying the concentration of the chosen catalyst. In terms of moles of catalyst per gram of zinc peroxide, manganous sulphate is approximately ten times as efficient in increasing the rate of, oxygen evolution as cupric sulfate, cobaltous sulfate, or auric chloride. For the uses contemplated more particularly herein, the optimum range of concentration of manganous sulfate is from 0.01 to 0.50 cc. of tenth-molarMnSOi solution per gram of zinc peroxide. Stated in another way, it may be said that in order to control the oxygen evolution so that oxygen may be released in substantial excess of 0.33 cc. during each hour (from 5 grams of zinc peroxide) of a 24-hour period, the quantity of M11304 should be approximately within the range from 0.015, to 0.75 gm. per grams of zinc peroxide.
The relatively less active catalyst can obviously be adjusted for adaptation to any given service requirements by appropriate increase in the amount of the catalyst to that of the zinc peroxide.
For practical purposes, the preparations contemplated herein comprise dry zinc peroxide and dry catalyst. which may be handled separately or in admixture. The dressings may be prepared extemporaneously by making a mixture of the zinc peroxide and catalyst into aslurry, or varying quantities of appropriate solutions of the catalyst may be added to make a slurry with the zinc peroxide.
The zinc peroxide best adapted for the medicinal use of oxygen in situ as referred to herein, is preferably prepared by reacting zinc chloride with sodium peroxide. h
It has been found that the zinc peroxide thus prepared is more definitely responsive to the action of the catalyst for the purposes of this invention over that: prepared, for instance, by the reaction of zinc oxide with hydrogen peroxide.
My invention is notlimited to any precisely defined proportions, as it will be obvious to those skilled in the art, from the disclosures herein, that these may be adjusted within reasonably wide limits to meet varying, specific requirements, and I am not to be limited, therefore. in the interpretation of my disclosure except as broadly .disclosed and as defined by the accompanying claims.
I claim as my invention:
1. A. preparation comprising zinc peroxide and an oxygen-evolving catalyst in the form of a water-soluble ionizable compound of gold.
2. As a new composition of matter, suitable for medicinal use, an aqueous slurry comprising zinc peroxide and a catalyst consisting of auric chloride.
THOMAS J. WEBB.
US2266835D Oxygen-evolving substance Expired - Lifetime US2266835A (en)

Publications (1)

Publication Number Publication Date
US2266835A true US2266835A (en) 1941-12-23

Family

ID=3432340

Family Applications (1)

Application Number Title Priority Date Filing Date
US2266835D Expired - Lifetime US2266835A (en) Oxygen-evolving substance

Country Status (1)

Country Link
US (1) US2266835A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429971A (en) * 1943-08-02 1947-10-28 Du Pont Method of preparing a therapeutic zinc peroxide composition
US2498343A (en) * 1944-08-10 1950-02-21 Lever Brothers Ltd Denture cleansers
DE1016241B (en) * 1952-01-30 1957-09-26 Zampoli & Brogi Process for the solidification of hydrogen peroxide
US4259205A (en) * 1977-10-06 1981-03-31 Halliburton Company Process involving breaking of aqueous gel of neutral polysaccharide polymer
DE3243012A1 (en) * 1982-11-20 1984-05-24 Dynamit Nobel Ag, 5210 Troisdorf Method of producing oxygen

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429971A (en) * 1943-08-02 1947-10-28 Du Pont Method of preparing a therapeutic zinc peroxide composition
US2498343A (en) * 1944-08-10 1950-02-21 Lever Brothers Ltd Denture cleansers
DE1016241B (en) * 1952-01-30 1957-09-26 Zampoli & Brogi Process for the solidification of hydrogen peroxide
US4259205A (en) * 1977-10-06 1981-03-31 Halliburton Company Process involving breaking of aqueous gel of neutral polysaccharide polymer
DE3243012A1 (en) * 1982-11-20 1984-05-24 Dynamit Nobel Ag, 5210 Troisdorf Method of producing oxygen

Similar Documents

Publication Publication Date Title
US3065139A (en) Anti-infectant topical preparations
US3856805A (en) Silver zinc allantoin complex
US2266835A (en) Oxygen-evolving substance
ES442215A1 (en) 1-(Bis-trifluoromethylphenyl)-2-oxo-pyrrolidine-4-carboxylic acid derivatives, their production and their use as plant-growth regulators and herbicides
DE1064046B (en) Process for the production of ethylene oxide
Williamson et al. Effect of cystine and methionine on healing of experimental wounds.
US2287847A (en) Oxygen-evolving substances
US3830824A (en) Physiological organic acid silver allantoinates
AU766031B2 (en) Iodine preparation compositon
US2385394A (en) Solid iodine compositions and methods for producing the same
DE2353136A1 (en) PROCESS FOR REACTIVATING PHOSPHORUS-VANADIUM-OXYGEN CATALYSTS
Finkle et al. Metabolism of Isolated Cellular Particles from Photo-synthetic Tissues: II. Oxidative decarboxylation of oxalic acid1.
US2904573A (en) Ferrous citrate complex
DE2042323A1 (en) Hematopoietic preparation
US2429971A (en) Method of preparing a therapeutic zinc peroxide composition
US1429276A (en) Tablet for producing iodine
US2250474A (en) Sterilization process
US2876159A (en) Dithiocarbamates for treatment of nickel poisoning
US2290710A (en) Morpholine periodide
US2312195A (en) Salts of dextro-ascorbic acid and method of preparing same
US3342675A (en) 2, 4, 5-trichlorophenol-lower-alkylamine reaction products as skin germicides
US3017325A (en) Therapeutic composition for topical application and method of applying the same
US3937740A (en) Process for the manufacture of 2,3,6-trimethylphenol
US2772947A (en) Process for converting nickel sulfide to nickel sulfate
JPH0156049B2 (en)